REPLIGEN CORP Q3 FY2026 earnings call

• Record Performance & Growth: Delivered record Q3 revenue of $209 million, outpacing market growth significantly despite lapping a strong prior year quarter.
• BioLife Acquisition: Successfully closed the acquisition of BioLife, expanding capabilities in cell therapy. Initial integration efforts are underway, including cost synergies from leadership consolidation and operational workshops.
• Capital Equipment Trends: Capital equipment orders hit a five-year high (mid-teens YoY growth), building a strong backlog for 2027. However, revenue recognition has been delayed as customers push deliveries into next year.
• Asia-Pacific Strategy: China showed robust >40% growth. Opened a new Refugee Training and Innovation Center in South Korea to support biologics and CDMO manufacturing hubs.
• Innovation & Services: Services revenue grew >20%, with systems under contract up nearly 40% YTD. Analytics franchise benefited from USP Chapter 507 recognition for Solo VP Plus technology.
• Strategic Initiatives: Launched Integrated Solution Team to address customer capacity expansion and onshoring needs. Continued investment in AI and digital twin capabilities for process development.

Total revenue reached $209 million, representing 12.5% organic growth. The Filtration segment declined 11% due to an ETF headwind and the PolyMEN divestiture, though it is expected to be flat to slightly down for the full year. Chromatography revenue grew over 50%, driven by Opus columns, with full-year guidance set for at least 30% growth. Proteins revenue increased more than 40%, supported by ligands and resins, with mid-teens growth expected for the year. Analytics achieved record 20% growth, with full-year guidance of at least 30%. BioLife (Cell Therapy) contributed approximately $24 million in Q4 following its acquisition.

• Full Year 2026 Revenue: Raised to $844–$852 million (midpoint $848 million), representing 12–13% organic growth (+50 bps). Assumes ~$24 million contribution from BioLife.
• Organic Growth Outlook: Narrowed to 12–13% for the full year, assuming Q4 growth aligns with the full-year range.
• Franchise Growth Expectations: Filtration flat to slightly down; Chromatography >30%; Proteins mid-teens; Analytics >30%.
• Margins: Adjusted operating margin guided to 16.0–16.3% (expansion of 220–250 bps). Gross margin expansion expected at 110–160 bps.
• EPS Guidance: Adjusted diluted EPS raised to $2.05–$2.09 (midpoint $2.07), up 21% at midpoint vs. 2025.
• 2027 Outlook: Expects reported top-line growth of at least 25% (ex-FX), exceeding $1 billion in revenue. Targets at least $0.05 per share accretion from BioLife in 2027.

• Filtration Headwinds: Significant decline in Filtration revenue (-11%) due to timing-related delays in ETF projects and the impact of the PolyMEN divestiture.
• Capital Equipment Recognition Lag: High order backlog has not yet translated into Q3/Q4 revenue, with most systems orders planned for delivery in 2027, creating near-term revenue visibility gaps.
• Integration Risks: BioLife integration involves executing synergy plans and improving cryo store scrap rates; initial assumptions for late 2026 are prudent.
• Macro/Market Uncertainty: Dependence on FDA approvals and capital equipment 'tap opening' for market recovery; potential foreign exchange fluctuations.

Q: Analyst asked about the cadence of BioLife integration benefits and assumptions regarding cell therapy market growth.

A: CEO stated immediate synergies include capturing public company costs, while long-term benefits involve improving CryoStore scrap rates. He noted confidence in the business model based on current commercial drug growth (>20%), assuming no new FDA approvals for two years, which has already occurred this year. CFO confirmed at least $0.05 accretion in 2027.

Q: Analyst inquired about the disconnect between strong capital equipment orders and lagging revenue, asking if the tap is opening.

A: CEO highlighted that Q3 orders were the highest in five years, setting up 2027 strongly. He described the market 'tap' as only 5-10% open, meaning significant upside remains. Decision-making velocity is slow, but the funnel is at record highs, with all recent orders recognized in 2027.

Q: Analyst asked about onshoring contributions to the order book and timeline.

A: CEO revealed they have won several RFPs this year, though not all are purely onshoring-related. He believes the true onshoring wave is delayed by 9-12 months compared to expectations. He anticipates seeing more pure onshoring RFPs next year, with deliveries primarily in 2028 and beyond.

Q: Analyst questioned the implied organic growth rate for 2027 and the conservatism of the high-single-digit market growth assumption.

A: CEO clarified this is not formal guidance but highlights a milestone of exceeding $1 billion in sales. He expects to outpace the market by >500 bps. Key swing factors for 2027 market growth are the pace of capital equipment pickup and FDA approval activity.

Q: Analyst asked about the attachment rate of analytics to filtration systems and drivers behind the trend.

A: CEO noted 75-80% of systems sold now include FlowVPX, driven by USP Chapter 507 recognition and the upgrade cycle of Solo VP. This integration differentiates their equipment offering. Service contracts are also up 40% YTD, supporting recurring revenue growth.